Not only did this approach suppress the prostate cancer EMT and metastasis through the regulation of the Akt/JNK and P38 MAPK pathways, but it also halted RUNX1-targeted EMT/metastasis strategies. Here, RUNX1 is linked to prostate carcinoma.